The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Open accessAbstract
Prostate cancer remains a leading cause of cancer death, as there are no durable means to treat advanced disease. Treatment of non-organ confined prostate cancer hinges on its androgen dependence. First line therapeutic strategies suppress androgen receptor (AR) activity, via androgen ablation and direct AR antagonists. While initially effective, incurable, "castration-resistant" tumors arise due to resurgent AR activity. Alterations of AR and/or associated regulatory networks are known to restore receptor activity and support resultant therapy-resistant tumor progression. However, recent evidence also reveals an unexpected contribution of AR ligand, wherein alterations in pathways controlling androgen synthesis support castrate-resistant AR activity. Herein, mechanisms underlying the lethal pairing of AR deregulation and aberrant androgen synthesis in prostate cancer progression will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 687
Formation of the Androgen Receptor Transcription Complex
Shang, Y., Myers, M., & Brown, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00471-9 · Cited by 672
Lin, C., Yang, L., Tanasa, B., Hutt, K., Ju, B.-G., Ohgi, K. A., Zhang, J., Rose, D. W., Fu, X.-D., Glass, C. K., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.030 · Cited by 576
Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Xu, J., Wu, R.-C., & O'Malley, B. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2695 · Cited by 488
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Jenster, G., van der Korput, H. A. G. M., Trapman, J., & Brinkmann, A. O. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7341 · Cited by 419
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer
Mani, R.-S., Tomlins, S. A., Callahan, K., Ghosh, A., Nyati, M. K., Varambally, S., Palanisamy, N., & Chinnaiyan, A. M. (2009) · Science · doi:10.1126/science.1178124 · Cited by 391
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
The backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347
AR, the cell cycle, and prostate cancer
Balk, S. P., & Knudsen, K. E. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06001 · Cited by 333
Self-citationStarving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
Self-citationAndrogen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
Labrie, F., Luu-The, V, Lin, S., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., & Belanger, A. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250001 · Cited by 278
Human aldo–keto reductases: Function, gene regulation, and single nucleotide polymorphisms
Penning, T. M., & Drury, J. E. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.04.024 · Cited by 266
Self-citationZhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 259
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Xu, K., Shimelis, H., Linn, D. E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.021 · Cited by 248
Agus, D. B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., & Scher, H. I. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1869 · Cited by 248
Latil, A., Bièche, I., Vidaud, D., Lidereau, R., Berthon, P., Cussenot, O., & Vidaud, M. (2001) · PubMed · Cited by 239
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Attar, R. M., Takimoto, C. H., & Gottardis, M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1171 · Cited by 212
Steinkamp, M. P., O'Mahony, O. A., Brogley, M., Rehman, H., LaPensee, E. W., Dhanasekaran, S., Hofer, M. D., Kuefer, R., Chinnaiyan, A., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3605 · Cited by 210
Post-translational modifications of steroid receptors
Faus, H., & Haendler, B. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.07.082 · Cited by 209
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Redman, M. W., Tangen, C. M., Goodman, P. J., Lucia, M. S., Coltman, C. A., & Thompson, I. M. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0092 · Cited by 204
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Agoulnik, I. U., Vaid, A., Bingman, W. E., Erdeme, H., Frolov, A., Smith, C. L., Ayala, G., Ittmann, M. M., & Weigel, N. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3541 · Cited by 202
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Taplin, M.-E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0765 · Cited by 197
Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., DeMayo, F. J., Tilley, W., & Greenberg, N. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408925102 · Cited by 192
The role of androgen receptor mutations in prostate cancer progression.
Brooke, G., & Bevan, C. (2009) · Current Genomics · doi:10.2174/138920209787581307 · Cited by 181
Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0017 · Cited by 179
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
Gaughan, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki141 · Cited by 174
Stanbrough, M., Leav, I., Kwan, P. W. L., Bubley, G. J., & Balk, S. P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191235898 · Cited by 169
Cai, C., Wang, H., Xu, Y., Chen, S., & Balk, S. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0395 · Cited by 169
Leon, C. G., Locke, J. A., Adomat, H. H., Etinger, S. L., Twiddy, A. L., Neumann, R. D., Nelson, C. C., Guns, E. S., & Wasan, K. M. (2010) · The Prostate · doi:10.1002/pros.21072 · Cited by 168
Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer
Ford, O. H., Gregory, C. W., Kim, D., Smitherman, A. B., & Mohler, J. L. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000091873.09677.f4 · Cited by 150
Vasaitis, T. S., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., Guo, Z., Fang, H., Njar, V. C. O., & Brodie, A. M. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0230 · Cited by 148
Byrns, M. C., Steckelbroeck, S., & Penning, T. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.008 · Cited by 145
Self-citationHey1, a Mediator of Notch Signaling, Is an Androgen Receptor Corepressor
Belandia, B., Powell, S. M., Garcia-Pedrero, J. M., Walker, M. M., Bevan, C. L., & Parker, M. G. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1425-1436.2005 · Cited by 137
Ponguta, L. A., Gregory, C. W., French, F. S., & Wilson, E. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802392200 · Cited by 128
Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors
Penning, T. M., Steckelbroeck, S., Bauman, D. R., Miller, M. W., Jin, Y., Peehl, D. M., Fung, K.-M. A., & Lin, H.-K. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.12.009 · Cited by 127
Self-citationKaikkonen, S., Jääskeläinen, T. J., Karvonen, U., Rytinki, M. M., Makkonen, H., Gioeli, D. G., Paschal, B. M., & Palvimo, J. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0219 · Cited by 121
Bauman, D. R., Steckelbroeck, S., Williams, M. V., Peehl, D. M., & Penning, T. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0287 · Cited by 120
Self-citationTestosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?
Poppel, H. V., & Nilsson, S. F. (2008) · Urology · doi:10.1016/j.urology.2007.12.070 · Cited by 107
Oefelein, M. G. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)62383-8 · Cited by 103
Comparison of clinical trials with finasteride and dutasteride.
Nickel, J. C. (2004) · Europe PMC (PubMed Central) · Cited by 103
Androgen receptor corepressors and prostate cancer
Burd, C. J., Morey, L. M., & Knudsen, K. E. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01115 · Cited by 96
Self-citationCyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
Comstock, C. E. S., Augello, M. A., Benito, R. P., Karch, J. M., Tran, T. H., Utama, F. E., Tindall, E. A., Wang, Y., Burd, C. J., Groh, E. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2865 · Cited by 94
Self-citationThe cyclin D1b splice variant: an old oncogene learns new tricks.
Knudsen, K. E. (2006) · Cell Division · doi:10.1186/1747-1028-1-15 · Cited by 93
Self-citationBrown, R. S. D., Edwards, J., Doǧan, A., Payne, H. A., Harland, S. J., Bartlett, J. M. S., & Masters, J. R. (2002) · The Journal of Pathology · doi:10.1002/path.1206 · Cited by 90
McCall, P. J., Gemmell, L., Mukherjee, R., Bartlett, J. M. S., & Edwards, J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604152 · Cited by 82
Chen, S., Kesler, C. T., Paschal, B. M., & Balk, S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.043133 · Cited by 80
5α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction
Rittmaster, R. S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.016 · Cited by 78
Locke, J. A., Guns, E. S. T., Lehman, M., Ettinger, S., Zoubeidi, A., Lubik, A. A., Margiotti, K., Fazli, L., Adomat, H. H., Wasan, K. M., et al. (2009) · The Prostate · doi:10.1002/pros.21057 · Cited by 73
Wang, L. G., Johnson, E. M., Kinoshita, Y., Babb, J. S., Buckley, M. T., Liebes, L., Melamed, J., Liu, X., Kurek, R., Ossowski, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6017 · Cited by 73
Ryan, C. J., Smith, A., Lal, P., Satagopan, J. M., Reuter, V. E., Scardino, P. T., Gerald, W. L., & Scher, H. I. (2006) · Urology · doi:10.1016/j.urology.2006.04.016 · Cited by 72
Wurzel, R. S., Ray, P., Major-Walker, K., Shannon, J. B., & Rittmaster, R. S. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500931 · Cited by 70
TRIM68 Regulates Ligand-Dependent Transcription of Androgen Receptor in Prostate Cancer Cells
Miyajima, N., Maruyama, S., Bohgaki, M., Kano, S., Shigemura, M., Shinohara, N., Nonomura, K., & Hatakeyama, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6059 · Cited by 69
EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Zhang, Y., Linn, D. E., Liu, Z., Melamed, J., Tavora, F. R. F., Young, C. Y. F., Burger, A. M., & Hamburger, A. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0526 · Cited by 68
Pre-receptor regulation of the androgen receptor
Penning, T. M., Jin, Y., Rižner, T. L., & Bauman, D. R. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.10.008 · Cited by 68
Self-citationDai, Y., Ngo, D., Jacob, J., Forman, L. W., & Faller, D. V. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn117 · Cited by 65
Klein, E. A., Ciezki, J. P., Kupelian, P. A., & Mahadevan, A. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.04.001 · Cited by 63
Oncogenic activation of androgen receptor
Kung, H.-J., & Evans, C. P. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.06.002 · Cited by 60
Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency
Andersson, S. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.1.130 · Cited by 59
Androgen Receptor Coactivators and Prostate Cancer
Agoulnik, I. U., & Weigel, N. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_23 · Cited by 58
DaSilva, J. O., Gioeli, D. G., Weber, M. J., & Parsons, S. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4687 · Cited by 58
Identification of the molecular switch that regulates access of 5α-DHT to the androgen receptor
Penning, T. M., Bauman, D. R., Jin, Y., & Rižner, T. L. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.12.007 · Cited by 57
Self-citationThe molecular biology of androgenic 17β-hydroxysteroid dehydrogenases
Andersson, S., Geissler, W. M., Patel, S., & Wu, L. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00039-3 · Cited by 54
Dart, D. A., Spencer‐Dene, B., Gamble, S. C., Waxman, J., & Bevan, C. L. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0028 · Cited by 53
Middleman, M. N., Lush, R. M., & Figg, W. D. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02967.x · Cited by 21
Combined Androgen Blockade: An Update
Klotz, L. H. (2006) · Urologic Clinics of North America · doi:10.1016/j.ucl.2005.12.001 · Cited by 21
Sartor, O., Nakabayashi, M., Taplin, M., Ross, R. W., Kantoff, P. W., Balk, S. P., & Oh, W. K. (2009) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2009.n.030 · Cited by 20
Docetaxel in the management of prostate cancer: current standard of care and future directions
Dosso, S. D., & Berthold, D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.11.1969 · Cited by 19
Hormonal approaches in prostate cancer: Application in the contemporary prostate cancer patient
Beekman, K. W., & Hussain, M. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.11.003 · Cited by 18
["Intracrinology". Autonomy and freedom of peripheral tissues].
Labrie, F., Bèlanger, A., Simard, J., Luu-The, V., & Labrie, C. (1995) · PubMed · Cited by 16
Cited by
Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D
Krishnan, A. V., & Feldman, D. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100611 · Cited by 470
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442
Self-citationHsieh, C.-L., Fei, T., Chen, Y., Li, T., Gao, Y., Wang, X., Sun, T., Sweeney, C. J., Lee, G.-S. M., Chen, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324151111 · Cited by 398
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.029 · Cited by 312
Rice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
Metadata
- Authors
- Knudsen, K. E., & Penning, T. M.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 21
- Issue
- 5
- Pages
- 315-324
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W2017896209
- Cited by
- 293
- References
- 95
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.